247 related articles for article (PubMed ID: 28055108)
1. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
Bernard B; Muralidhar V; Chen YH; Sridhar SS; Mitchell EP; Pettaway CA; Carducci MA; Nguyen PL; Sweeney CJ
Cancer; 2017 May; 123(9):1536-1544. PubMed ID: 28055108
[TBL] [Abstract][Full Text] [Related]
2. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
[TBL] [Abstract][Full Text] [Related]
3. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
4. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
6. Impact of androgen deprivation therapy on racial/ethnic disparities in the survival of older men treated for locoregional prostate cancer.
Holmes L; Chan W; Jiang Z; Ward D; Essien EJ; Du XL
Cancer Control; 2009 Apr; 16(2):176-85. PubMed ID: 19337204
[TBL] [Abstract][Full Text] [Related]
7. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
8. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Sweeney CJ; Chen YH; Carducci M; Liu G; Jarrard DF; Eisenberger M; Wong YN; Hahn N; Kohli M; Cooney MM; Dreicer R; Vogelzang NJ; Picus J; Shevrin D; Hussain M; Garcia JA; DiPaola RS
N Engl J Med; 2015 Aug; 373(8):737-46. PubMed ID: 26244877
[TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer.
Rasmussen KM; Patil V; Li C; Yong C; Appukkuttan S; Grossman JP; Jhaveri J; Halwani AS
JAMA Netw Open; 2023 Oct; 6(10):e2337272. PubMed ID: 37819658
[TBL] [Abstract][Full Text] [Related]
10. Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
Harshman LC; Wang VX; Hamid AA; Santone G; Drake CG; Carducci MA; DiPaola RS; Fichorova RN; Sweeney CJ
Prostate; 2020 Dec; 80(16):1429-1437. PubMed ID: 32949185
[TBL] [Abstract][Full Text] [Related]
11. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
Rydzewska LHM; Burdett S; Vale CL; Clarke NW; Fizazi K; Kheoh T; Mason MD; Miladinovic B; James ND; Parmar MKB; Spears MR; Sweeney CJ; Sydes MR; Tran N; Tierney JF;
Eur J Cancer; 2017 Oct; 84():88-101. PubMed ID: 28800492
[TBL] [Abstract][Full Text] [Related]
12. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
Dall'Era MA; deVere-White R; Rodriguez D; Cress R
Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
[TBL] [Abstract][Full Text] [Related]
13. Differences in breast cancer stage, treatment, and survival by race and ethnicity.
Li CI; Malone KE; Daling JR
Arch Intern Med; 2003 Jan; 163(1):49-56. PubMed ID: 12523916
[TBL] [Abstract][Full Text] [Related]
14. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Kyriakopoulos CE; Chen YH; Carducci MA; Liu G; Jarrard DF; Hahn NM; Shevrin DH; Dreicer R; Hussain M; Eisenberger M; Kohli M; Plimack ER; Vogelzang NJ; Picus J; Cooney MM; Garcia JA; DiPaola RS; Sweeney CJ
J Clin Oncol; 2018 Apr; 36(11):1080-1087. PubMed ID: 29384722
[TBL] [Abstract][Full Text] [Related]
15. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
[TBL] [Abstract][Full Text] [Related]
16. State-specific prevalence of selected health behaviors, by race and ethnicity--Behavioral Risk Factor Surveillance System, 1997.
Bolen JC; Rhodes L; Powell-Griner EE; Bland SD; Holtzman D
MMWR CDC Surveill Summ; 2000 Mar; 49(2):1-60. PubMed ID: 10965781
[TBL] [Abstract][Full Text] [Related]
17. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
[TBL] [Abstract][Full Text] [Related]
18. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.
Ostrom QT; Cote DJ; Ascha M; Kruchko C; Barnholtz-Sloan JS
JAMA Oncol; 2018 Sep; 4(9):1254-1262. PubMed ID: 29931168
[TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
20. Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer.
Ni X; Luu M; Ma W; Zhang T; Wei Y; Freedland SJ; Ye D; Daskivich TJ; Zhu Y
J Natl Compr Canc Netw; 2023 Jul; 21(7):733-741.e3. PubMed ID: 37433430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]